GLP-1 analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Another independent approach is to use oligoadenylated anti-telomerase antisense oligonucleotides and ribozymes to target telomerase RNA, leading to the dissociation of the RNA and to apoptosis (Figure 5). The fast induction of apoptosis through antisense binding may be a good alternative to the slower telomere shortening.
== Electrospray ionization == Electrospray ionization (ESI) is a technique that involves using high voltages to create an electrospray, or a fine aerosol created by the high voltages. ESI sample preparation can be very important and the quality of results can be heavily determined by the characteristics of the sample. ESI experiments can be run on-line or off-line. In on-line measurements the mass spectrometer is connected to a liquid chromatograph and as the samples are separated they are ionized into the mass spectrometer by the ESI system; sample preparation is actually performed before the LC separation. In off-line measurements, the analyte solution is applied directly to the mass spectrometer by a spray capillary . Off-line sample preparation has many considerations, such as the fact that the capillary used allows for the application of volumes in the nanoliter range, which can contain a concentration too small for analysis of many compounds, such as proteins. An additional problem can be loss of ESI signal due to interference between the analyte sample and background components. Unfortunately, it has been shown that sample preparation itself can only slightly alleviate this problem which is due more to the nature of the analyte itself than the preparation. In ESI the principal problem comes not from reactions in the gas phase but rather from problems involving the solution phase of the droplets themselves.
The discussion about possible health risks from mobile phone radiation has been controversial to date, although there are currently no valid results. According to the German Federal Office for Radiation Protection
In the first step of peptidoglycan synthesis, glutamine, which is an amino acid, donates an amino group to a sugar, fructose 6-phosphate. This reaction, catalyzed by EC 2.6.1.16 (GlmS), turns fructose 6-phosphate into glucosamine-6-phosphate. In step two, an acetyl group is transferred from acetyl CoA to the amino group on the glucosamine-6-phosphate creating N-acetyl-glucosamine-6-phosphate. This reaction is EC 5.4.2.10, catalyzed by GlmM. In step three of the synthesis process, the N-acetyl-glucosamine-6-phosphate is isomerized, which will change N-acetyl-glucosamine-6-phosphate to N-acetyl-glucosamine-1-phosphate. This is EC 2.3.1.157, catalyzed by GlmU. In step 4, the N-acetyl-glucosamine-1-phosphate, which is now a monophosphate, attacks UTP. Uridine triphosphate, which is a pyrimidine nucleotide, has the ability to act as an energy source. In this particular reaction, after the monophosphate has attacked the UTP, an inorganic pyrophosphate is given off and is replaced by the monophosphate, creating UDP-N-acetylglucosamine (2,4). (When UDP is used as an energy source, it gives off an inorganic phosphate.) This initial stage, is used to create the precursor for the NAG in peptidoglycan. This is EC 2.7.7.23, also catalyzed by GlmU, which is a bifunctional enzyme. In step 5, some of the UDP-N-acetylglucosamine (UDP-GlcNAc) is converted to UDP-MurNAc (UDP-N-acetylmuramic acid) by the addition of a lactyl group to the glucosamine. Also in this reaction, the C3 hydroxyl group will remove a phosphate from the alpha carbon of phosphoenolpyruvate.
Sources: en.wikipedia.org
Since the release of nonbenzodiazepines, also known as z-drugs, in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), and less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010). It is not clear as to whether the new non benzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar. According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side-effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines. Some experts suggest using nonbenzodiazepines preferentially as a first-line long-term treatment of insomnia. However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and the patient's preference. Older adults should not use benzodiazepines to treat insomnia unless other treatments have failed.
==== Communist insurgency ==== Duterte described himself as left-leaning during his presidential campaign. As he initially had good relations with the left, he received campaign support from leftist groups, particularly in Mindanao. Duterte was a student of Communist Party of the Philippines (CPP) founder Jose Maria Sison at Lyceum of the Philippines University, and Sison stated during the election campaign that Duterte was "the best President the Philippines can have since Marcos". Upon Duterte's election into office, prospects of restarting peace talks between the Philippine government and the CPP-NPA-NDF, which stalled in 2011, gained momentum. Duterte temporarily released several communist prisoners, notably couples CPP-NPA chairman Benito and CPP-NPA secretary-general Wilma Tiamzon, to join the peace talks in Oslo. In addition, Duterte offered positions for left-leaning activists in his administration, notably in four executive departments: Agrarian Reform, Environment and Natural Resources, Social Welfare and Development, and Labor and Employment. In the months leading to 2017, however, the Duterte administration and the CPP accused each other of not being faithful to the ongoing peace negotiations. The CPP demanded from the administration the release of around 130 political detainees, which—along proposals of the CPP to form a "coalition government"— Duterte declined. Additionally, several leftists appointed by Duterte were rejected by the Commission on Appointments, while others resigned or were fired by Duterte amidst the tense relations.
==== Academic honesty ==== Generative AI can be used to generate and modify academic prose, paraphrase sources, and translate languages. The use of generative AI in a classroom setting has challenged traditional definitions of academic plagiarism, leading to a "cat-and-mouse" dynamic between students using AI and institutions attempting to detect it. In the immediate wake of ChatGPT's release, many school districts and universities issued temporary bans on the technology, though many institutions have since moved toward policies of managed integration. However, the implementation of these policies often lacks clarity. Research suggests that the burden of interpreting "acceptable use" frequently falls on individual students and teachers, creating an environment where academic honesty becomes difficult to define and enforce. A commonly proposed use for teachers is grading and giving feedback. Companies like Pearson and ETS use AI to score grammar, mechanics, usage, and style, but not for main ideas or overall structure. The National Council of Teachers of English stated that machine scoring makes students feel their writing is not worth reading. AI scoring has also given unfair results for students from different ethnic backgrounds.
Epithelium – innermost layer. Responsible for most digestive, absorptive and secretory processes. Lamina propria – a layer of loose connective tissue. Unusually cellular compared to most connective tissue Muscularis mucosae – a thin layer of smooth muscle that aids the passing of material and enhances the interaction between the epithelial layer and the contents of the lumen by agitation and peristalsis The mucosae are highly specialized in each organ of the gastrointestinal tract to deal with the different conditions. The most variation is seen in the epithelium.
=== Properties === In terms of molecular structure, synephrine has a phenethylamine skeleton, with a phenolic hydroxy- group, an alcoholic hydroxy- group, and an N-methylated amino-group. Alternatively, synephrine might be described as a phenylethanolamine with an N-methyl and p-hydroxy substituent. The amino-group confers basic properties on the molecule, whereas the phenolic –OH group is weakly acidic: the apparent (see original article for discussion) pKas for protonated synephrine are 9.55 (phenolic H) and 9.79 (ammonium H). Common salts of racemic synephrine are its hydrochloride, C9H13NO2.HCl, m.p. 150–152°, the oxalate (C9H13NO2)2.C2H2O4, m.p. 221–222 °C, and the tartrate (Sympatol), (C9H13NO2)2.C4H6O6, m.p. 188–190 °C. The presence of the hydroxy-group on the benzylic C of the synephrine molecule creates a chiral center, so the compound exists in the form of two enantiomers, d- and l- synephrine, or as the racemic mixture, d,l- synephrine. The dextrorotatory d-isomer corresponds to the (S)-configuration, and the levorotatory l-isomer to the (R)-configuration. Racemic synephrine has been resolved using ammonium 3-bromo-camphor-8-sulfonate. The enantiomers were not characterized as their free bases, but converted to the hydrochloride salts, with the following properties: (S)-(+)-C9H13NO2.HCl: m.p. 178 °C; [α] = +42.0°, c 0.1 (H2O); (R)-(−)-C9H13NO2.HCl: m.p. 176 °C; [α] = −39.0°, c 0.2 (H2O) (−)-Synephrine, as the free base isolated from a Citrus source, has m.p. 162–164 °C (with decomposition). The X-ray structure for synephrine has been determined.
Sources: en.wikipedia.org
=== Refugee Lodges of Hispaniola === In 1748, on Cuba's neighboring island of Hispaniola, Freemasonry in Haiti was established by the Grande Loge de France with the St. Jean de Jérusalem Ecossais (English: St. John of Jerusalem) in Cap-Français, Saint-Domingue (known today as Haiti). The second Haitain Lodge was chartered in 1765 at Los Cayos, called Les Frères Réunis No. 1 (English: Reunited Brothers). When the Haitian Revolution started, a mass exodus of French and Saint-Domingue Creole refugee emigres left Saint-Domingue and settled in Cuba. Freemasonry was allowed to continue for some time during the war in Saint-Domingue, where Huet de la Chapelle had become the Grand Master of the French Provincial Grand Loge in 1795, until a change in government forced the Haitian Lodges to flee the island and relocate elsewhere. As that conflict then spilled over the border into Santo Domingo (known today as the Dominican Republic), the Eastern half of that island also experienced a wave of emigration as Spaniards fled the colony. Most of these refugees from Saint-Domingue and Santo Domingo landed in the port towns of Oriente Province, especially Baracoa and Santiago de Cuba. In 1798, La Bénéfique Concorde was reestablished in Baracoa, La Persévérance was reestablished in Santiago de Cuba, and La Concorde L'Amitié relocated to Havana. The charters for these French Lodges, however, specifically limited their activities to Hispaniola.
Residency or postgraduate training is a stage of graduate medical education. It refers to a qualified physician (one who holds the degree of MD, DO, MBBS/MBChB), veterinarian (DVM/VMD, BVSc/BVMS), dentist (DDS or DMD), podiatrist (DPM), optometrist (OD), pharmacist (PharmD), physical therapist (DPT), or Medical Laboratory Scientist (Doctor of Medical Laboratory Science) who practices medicine or surgery, veterinary medicine, dentistry, optometry, podiatry, clinical pharmacy, physical therapy, or Clinical Laboratory Science, respectively, usually in a hospital or clinic, under the direct or indirect supervision of a senior medical clinician registered in that specialty such as an attending physician or consultant. The term residency is named as such due to resident physicians (resident doctors) of the 19th century residing at the dormitories of the hospital in which they received training. In many jurisdictions, successful completion of such training is a requirement in order to obtain an unrestricted license to practice medicine, and in particular a license to practice a chosen specialty. In the meantime, they practice "on" the license of their supervising physician. An individual engaged in such training may be referred to as a resident physician, house officer, registrar or trainee depending on the jurisdiction. Residency training may be followed by fellowship or sub-specialty training.
== History == Z-drugs emerged in the last years of the 1980s and early 1990s, with zopiclone (Imovane) approved by the British National Health Service as early as 1989, quickly followed by Sanofi with zolpidem (Ambien). By 1999, King Pharmaceuticals had finalized approval with the American Food and Drug Administration (FDA) to market zaleplon (Sonata, Starnoc) across the US. In 2005, the FDA approved eszopiclone (Lunesta) the (S)-enantiomer of zopiclone. That same year, 2005, the FDA finalized approval for Ambien CR, or extended-release zolpidem. Most recently, in 2012 the FDA approved Intermezzo (zolpidem tartate sublingual), which is marketed for middle-of-the-night insomnia, available in doses only half of the strength of immediate-release zolpidem tartrate to avoid residual next-day sedation.
A preliminary study of ovulation inhibition in women found that oral CEEs was 33% effective at 1.25 mg/day and 94% at 3.75 mg/day. A dosage of oral CEEs of 2.5 mg three times daily (7.5 mg/day total) has been found to suppress total testosterone levels in men to an equivalent extent as 3 mg/day oral diethylstilbestrol, which is the minimum dosage of diethylstilbestrol required to consistently suppress total testosterone levels into the castrate range (<50 ng/dL).
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.